TA invests in Biocomposites

TA is currently investing from its 12th fund, which held a final close on $5.3bn in June 2015.

The firm's previous investments in the European healthcare space include a £35m expansion deal for Ireland-based Quotient Bioresearch in 2008; the acquisition of a majority stake in Austria-based dental reconstruction technology company Amann Girrbach in 2010; and a 2015 deal for Belgium-based Physiol.

Company
Founded in 1996 and headquartered in Keele, Staffordshire, Biocomposites develops calcium compounds for surgical use, with a particular focus on orthopaedic procedures. The company distributes its products directly to hospitals and through independent distributors, with the majority of its sales generated in the US. It has additional sales offices in Wilmington, North Carolina and Shanghai, China.

Biocomposites generated a turnover of £15.7m in 2015, according to publicly available documents, with an operating profit of £7.8m.

People
TA Associates – Birker Bahnsen (managing director).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• UK / Ireland
• Healthcare
• United Kingdom
• TA Associates